Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

已完结 10 由大三发布于 2026/11/1 19:59:30

DOI:10.1016/s0140-6736(25)01576-4
作者：Linda Stein Gold, April W Armstrong, Robert Bissonnette, Nina Magnolo, Ronald B Vender, Michael Sebastian, Maria Laura Galimberti, Athanasios Tsianakas, Marcelo Arnone, Paul Wallace, Margrit Simon, Jo
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundMonoclonal antibodies targeting interleukin-23 and interleukin-12 are efficacious in treating plaque psoriasis but must be delivered via intravenous or subcutaneous injection. Here

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SageHow intentional is incidental learning? Learners, words, task types, and learning gains